This company listing is no longer active
TCON Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
TRACON Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.032 |
| 52 Week High | US$14.75 |
| 52 Week Low | US$0.002 |
| Beta | 1.4 |
| 1 Month Change | -19.50% |
| 3 Month Change | -51.94% |
| 1 Year Change | -99.23% |
| 3 Year Change | -99.94% |
| 5 Year Change | -99.94% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| TCON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 23.4% | 5.1% | -1.1% |
| 1Y | -99.2% | -14.9% | 9.1% |
Return vs Industry: TCON underperformed the US Biotechs industry which returned 15% over the past year.
Return vs Market: TCON underperformed the US Market which returned 32.2% over the past year.
Price Volatility
| TCON volatility | |
|---|---|
| TCON Average Weekly Movement | 61.3% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: TCON's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TCON's weekly volatility has increased from 49% to 61% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 17 | Craig Jalbert | www.traconpharma.com |
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company’s clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors.
TRACON Pharmaceuticals, Inc. Fundamentals Summary
| TCON fundamental statistics | |
|---|---|
| Market cap | US$109.72k |
| Earnings (TTM) | US$5.20m |
| Revenue (TTM) | US$3.20m |
Is TCON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCON income statement (TTM) | |
|---|---|
| Revenue | US$3.20m |
| Cost of Revenue | US$12.11m |
| Gross Profit | -US$8.91m |
| Other Expenses | -US$14.10m |
| Earnings | US$5.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.52 |
| Gross Margin | -278.31% |
| Net Profit Margin | 162.34% |
| Debt/Equity Ratio | 0% |
How did TCON perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/04 14:58 |
| End of Day Share Price | 2024/12/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TRACON Pharmaceuticals, Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Cross | Alliance Global Partners |
| Joel Beatty | Baird |
| null null | BTIG |